Researchers identified a set of genetic changes that predict whether melanoma patients will respond to checkpoint inhibitor therapies. It’s what’s missing in the tumor genome, not what’s mutated, that thwarts treatment of metastatic melanoma with immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center report in Science Translational Medicine. Whole...